Deterioration in basketball skill performance accompanies two percent dehydration in skilled 12- to 15-yr-old basketball players. Additionally, EUH with a 6% CES significantly improves shooting performance and on-court sprinting over EUH with water.
Basketball players experienced a progressive deterioration in performance as DEH progressed from 1 to 4%. The threshold, or % DEH at which the performance decrement reached statistical significance, was 2% for combined timed and shooting drills.
Studies are reported on changes in fatty acid and lipid class composition in developing soybeans picked at intervals from ca. nine days after flowering to maturity. In the early stages of development of the
Background
Suboptimal vitamin D status is prevalent in HIV-infected patients and associated with increased risk of disease severity and morbidity. We aimed to determine 12-mo safety and efficacy of daily 7000IU vitamin D3 (vitD3) vs placebo to sustain increased serum 25-hydroxyvitamin D (25(OH)D) and improve immune status in HIV-infected subjects.
Methods
This was a double-blind trial of perinatally- (PHIV) or behaviorally-acquired (BHIV) HIV-infected subjects (5.0–24.9y). Safety, 25(OH)D-related parameters, and immune status were assessed at baseline, 3, 6, and 12 months.
Results
Fifty-eight subjects enrolled (67% male, 85% African-American, 64% BHIV) and 50 completed with no safety concerns. In unadjusted analyses, there were no differences between randomization groups at baseline; at 3, 6, and 12 months, 25(OH)D was higher with supplementation than baseline and higher than with placebo (P<0.05). In adjusted mixed models, in the supplementation group, the fixed effect of 25(OH)D was higher (P<0.001). Percentage of naïve T helper cells (Th naïve%) were significantly (P<0.01) and T helper cells (CD4%) marginally (P<0.10) increased with supplementation in those taking highly active antiretroviral therapy (HAART), and RNA viral load was reduced (P ≤ 0.05). In exploratory linear models, change in 25(OH)D predicted RNA viral load at 3 and 12 months and CD4% at 3 months (P<0.05).
Conclusions
Daily 7000IU vitD3 for 12 months was safe in HIV-infected subjects and effective in increasing 25(OH)D. Supplementation improved in some clinically important HIV immune markers in subjects on HAART. Adjunct therapy with high-dose, daily vitD3 for HIV-infected subjects and for those on/off HAART requires further investigation.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.